B+
Bull case
25%
Probability
Target price
$34.00
+62.8% vs current
ACAD
ACADIACNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$28.00
+34.0% vs current
B-
Bear case
25%
Probability
Target price
$15.00
-28.2% vs current
AI sentiment snapshot
Latest data as of 2026-05-20
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+74.9
Score
AI commentary
Primary-source tone is constructive because revenue grew, both marketed products contributed, guidance was reaffirmed, and the May 2026 8-K exhibit identifies two dated 2H2026 program milestones. The offset is higher commercial spending, modest Q1 earnings power, and limited visible analyst-revision support in the packet. No social-context signal was available, so sentiment should not override the cautious primary-source monitoring view.
RankAlpha Sentiment Codex - 2026-05-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06eventQ1 2026 results and FY2026 guidance reaffirmed [#8-K-2026-05-06]Medium impact
Acadia reported total revenue of $268M, DAYBUE sales of $101M (+20% y/y), NUPLAZID sales of $167M (+6% y/y on a non-GAAP adjusted basis), net income of $4M, and reaffirmed full-year 2026 guidance; the offset was much higher SG&A at $171M vs. $126M a year ago.
2026-09-15catalystRemlifanserin Phase 2 topline readout in Alzheimer disease psychosis [#8-K-2026-05-06]High impact
The company said Phase 2 topline results for remlifanserin in Alzheimer disease psychosis remain on track for the August to October 2026 timeframe. This is a company-specific forward catalyst, but it is binary and should be treated as a monitoring item rather than a confirmed positive driver.
2026-10-15catalystTrofinetide Japan trial topline results [#8-K-2026-05-06]Medium impact
Acadia said accelerated enrollment in the trofinetide clinical trial in Japan moved expected topline results to the September to November 2026 timeframe, giving the stock a second dated program-specific milestone in 2H2026.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-20 • Updated nightlySource: Internal modelMethodology